PainReform Ltd.

General Information

(Note: This is an offering of 2.55 million units, according to an SEC filing on Aug. 24, 2020, in which the IPO was changed to a unit offering from one of common shares. Each unit consists of one of our ordinary shares and one warrant to purchase one ordinary share. We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “PRFX”. The Warrants will not be listed for trading and will expire five years from the date of issuance.)

We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended release drug-delivery system prolongs the in vivo activity of APIs (active pharmaceutical ingredients), thus increasing the therapeutic window for patient treatment. Our strategy is to incorporate generic drugs with our proprietary extended release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (“FDA”). 

Employees: 3
Founded: 2007
Contact Information
Address 60C Medinat Hayehudim, Herzliya, 4676670, Israel
Phone Number +972 9-960-1901
Web Address
View Prospectus: PainReform Ltd.
Financial Information
Market Cap $71.29mil
Revenues $0 mil (last 12 months)
Net Income $-1.3 mil (last 12 months)
IPO Profile
Symbol PRFX
Exchange NASDAQ
Shares (millions): 2.5
Price range $8.00 - $8.00
Est. $ Volume $20.0 mil
Manager / Joint Managers Maxim Group/ Joseph Gunnar
CO-Managers -
Expected To Trade: 9/1/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change